ClearBridge Investments
AIMT

ClearBridge Investments’s Aimmune Therapeutics AIMT Stock Holding History

ClearBridge Investments’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-200
Closed -$5K – 1226
2017
Q3 		$5K Hold
200
– – ﹤0.01% 1127
2017
Q2 		$4K Hold
200
– – ﹤0.01% 1148
2017
Q1 		$4K Hold
200
– – ﹤0.01% 1108
2016
Q4 		$4K Hold
200
– – ﹤0.01% 1138
2016
Q3 		$3K Hold
200
– – ﹤0.01% 1101
2016
Q2 		$2K Hold
200
– – ﹤0.01% 1053
2016
Q1 		$3K Hold
200
– – ﹤0.01% 1036
2015
Q4 		$4K Hold
200
– – ﹤0.01% 1084
2015
Q3 		$5K Buy
+200
New +$4.68K ﹤0.01% 1123

Other funds holding AIMT

FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AC
Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

ClearBridge Investments's AIMT Position: Q4 2017 in Review

ClearBridge Investments sold out of Aimmune Therapeutics (AIMT) in Q4 2017, closing a stake of 200 shares — an estimated $5K sold.

ClearBridge Investments first reported a position in AIMT in Q3 2015 and held it in 9 quarters. The position peaked at $5K in Q3 2017. 129 funds tracked by Wall St. Rank hold AIMT as of Q4 2017.

  • ClearBridge Investments reported no remaining Aimmune Therapeutics position as of Q4 2017 after selling out during the quarter.
  • ClearBridge Investments sold 200 Aimmune Therapeutics shares in Q4 2017, an estimated $5K.
  • ClearBridge Investments first reported a position in Aimmune Therapeutics in Q3 2015 and held it in 9 quarters.
  • ClearBridge Investments's Aimmune Therapeutics position peaked at $5K in Q3 2017.
  • 129 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2017.

Based on ClearBridge Investments's 13F filing for Q4 2017, filed 14 Feb 2018.